Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 1.11 below Ionis Pharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 340 other companies have achieved higher Quick Ratio than Ionis Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1053 to 1876.

Explain Quick Ratio?
How much Cash & cash equivalents IONS�s has?
What are IONS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IONS Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) 2025	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-58.02 %	186.3 %	87.23 %	196.64 %	346.85 %
Y / Y Cash & cash equivalent Change	17.75 %	-10.54 %	-83.8 %	-9.79 %	-94.31 %
Quick Ratio MRQ	1.11	2.68	0.64	2.48	0.4
IONS's Total Ranking	# 1876	# 1053	# 1014	# 812	#
Seq. Current Liabilities Change	-55.95 %	23.73 %	-35.9 %	20.15 %	200.43 %
Seq. Cash & cash equivalent Change	-81.76 %	415.53 %	-83.38 %	653.5 %	-86.14 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 341
Healthcare Sector	# 608
Overall Market	# 1876

Quick Ratio Statistics
High	Average	Low
51.75	7.83	0.4
(Jun 30 2023)		(Jun 30 2025)

Financial Statements
Ionis Pharmaceuticals Inc 's Current Liabilities	$ 316 Millions	Visit IONS's Balance sheet
Ionis Pharmaceuticals Inc 's Cash & cash equivalent	$ 350 Millions	Visit IONS's Balance sheet
Source of IONS's Sales		Visit IONS's Sales by Geography

Cumulative Ionis Pharmaceuticals Inc 's Quick Ratio

IONS's Quick Ratio for the trailling 12 Months

IONS Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	55.61 %	185.84 %	123.9 %	71.74 %	16.32 %
Y / Y Cash & cash equivalent TTM Growth	-32.42 %	-60.25 %	-58.59 %	-42.98 %	-39.77 %
Quick Ratio TTM	1.94	1.64	2.03	3.15	4.47
Total Ranking TTM	# 4012	# 3887	# 3128	# 1474	#
Seq. Current Liabilities TTM Growth	-14.78 %	18.77 %	12.18 %	37.06 %	56.53 %
Seq. Cash & cash equivalent TTM Growth	1.09 %	-4.47 %	-27.58 %	-3.37 %	-40.53 %

Quick ratio ranking by company, industry and sector >> Back to IONS Financial Strength Comparisons >> Go to Compare IONS Quick Ratio to its Competitors

On the trailing twelve months basis IONS Cash & cash equivalent increased by 17.75 % in Q2 2026 year on year, while Current Liabilities dropped to $316 millions, this led to increase in in Ionis Pharmaceuticals Inc 's Quick Ratio to 1.94, Quick Ratio remained below IONS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Ionis Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3887 to 4012.

Explain Quick Ratio?
How much Cash & cash equivalents IONS�s has?
What are IONS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 438
Healthcare Sector	# 899
Within the Market	# 4012

trailing twelve months Quick Ratio Statistics
High	Average	Low
16.47	6.92	1.08
(Jun 30 2023)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Tg Therapeutics Inc	3.02	$ 811.665 Millions	$ 268.493 Millions
Dermata Therapeutics Inc	3.02	$ 4.413 Millions	$ 1.462 Millions
Xilio Therapeutics Inc	2.99	$ 136.040 Millions	$ 45.487 Millions
Cadrenal Therapeutics Inc	2.99	$ 4.476 Millions	$ 1.497 Millions
Zevra Therapeutics Inc	2.99	$ 145.321 Millions	$ 48.632 Millions
Inhibitor Therapeutics Inc	2.95	$ 0.516 Millions	$ 0.175 Millions
Annovis Bio Inc	2.95	$ 18.736 Millions	$ 6.359 Millions
Puma Biotechnology Inc	2.89	$ 144.164 Millions	$ 49.825 Millions
Ptc Therapeutics inc	2.89	$ 2,229.082 Millions	$ 771.068 Millions
Werewolf Therapeutics Inc	2.80	$ 21.987 Millions	$ 7.863 Millions
Alzamend Neuro Inc	2.77	$ 7.591 Millions	$ 2.739 Millions
Scienture Holdings Inc	2.71	$ 8.188 Millions	$ 3.026 Millions
Acadia Pharmaceuticals Inc	2.65	$ 956.474 Millions	$ 361.436 Millions
Edesa Biotech Inc	2.63	$ 10.300 Millions	$ 3.910 Millions
Hepion Pharmaceuticals Inc	2.63	$ 1.629 Millions	$ 0.620 Millions
Stoke Therapeutics Inc	2.62	$ 110.004 Millions	$ 41.930 Millions
Elicio Therapeutics Inc	2.55	$ 23.480 Millions	$ 9.202 Millions
Palatin Technologies Inc	2.55	$ 7.492 Millions	$ 2.938 Millions
Adc Therapeutics Sa	2.54	$ 219.107 Millions	$ 86.332 Millions
Beone Medicines Ltd	2.50	$ 5,290.368 Millions	$ 2,119.187 Millions
Ironwood Pharmaceuticals inc	2.41	$ 79.127 Millions	$ 32.854 Millions
Schrodinger Inc	2.38	$ 413.739 Millions	$ 173.845 Millions
Insmed Inc	2.37	$ 1,160.312 Millions	$ 490.508 Millions
Biovie Inc	2.37	$ 8.977 Millions	$ 3.796 Millions
Tao Synergies Inc	2.30	$ 2.368 Millions	$ 1.032 Millions
Madrigal Pharmaceuticals Inc	2.24	$ 839.419 Millions	$ 374.204 Millions
Rockwell Medical inc	2.23	$ 24.936 Millions	$ 11.174 Millions
Ars Pharmaceuticals Inc	2.22	$ 143.845 Millions	$ 64.728 Millions
Alnylam Pharmaceuticals Inc	2.19	$ 3,308.147 Millions	$ 1,512.513 Millions
Xeris Biopharma Holdings Inc	2.16	$ 243.494 Millions	$ 112.826 Millions

Date modified: 2026-08-13T08:57:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.